Identification of a Novel Function of CX-4945 as a Splicing RegulatorReport as inadecuate

Identification of a Novel Function of CX-4945 as a Splicing Regulator - Download this document for free, or read online. Document in PDF available to download.

Alternative splicing is a nearly ubiquitous versatile process that controls gene expression and creates numerous protein isoforms with different functions from a single gene. The significance of alternative splicing has been confirmed by the increasing number of human diseases that are caused by misregulation of splicing events. Very few compounds, however, have been reported to act as inhibitors of alternative splicing, and their potential clinical use needs to be evaluated. Here, we report that CX-4945, a previously well-characterized inhibitor of casein kinase 2 CK2 and a molecule currently in clinical trials Phase II for cancer treatment, regulates splicing in mammalian cells in a CK2-independent manner. Transcriptome-wide analysis using exon array also showed a widespread alteration in alternative splicing of numerous genes. We found that CX-4945 potently inhibits the Cdc2-like kinases Clks in vitro and in turn, leads to suppression of the phosphorylation of serine-arginine-rich SR proteins in mammalian cells. Surprisingly, the overall efficacy of CX-4945 on Clks IC50 = 3–90 nM was stronger than that of TG-003, the strongest inhibitor reported to date. Of the Clks, Clk2 was most strongly inhibited by CX-4945 in an ATP-competitive manner. Our research revealed an unexpected activity of the drug candidate CX-4945 as a potent splicing modulator and also suggested a potential application for therapy of diseases caused by abnormal splicing.

Author: Hyeongki Kim, Kwangman Choi, Hyunju Kang, So-Young Lee, Seung-Wook Chi, Min-Sung Lee, Jaehyoung Song, Donghwa Im, Yura Choi, Sung



Related documents